Home›Research›Compare›GLP-2 vs TB-500
Peptide ComparisonGLP-2 vs TB-500
Both are Tissue Repair peptides.
GLP-2
Glucagon-like Peptide-2
11 providers listed
TB-500
thymosin beta 4
Half-life: 5–7 days
402 providers listed
GLP-2 is FDA-approved, while TB-500 is banned from compounding — the clearest structural difference between them.
GLP-2
Evidence
Half-life
—
TB-500
Evidence
Half-life
5–7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | GLP-2 |
| Further along in FDA review | GLP-2 |
| More provider options (11 vs 402) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
GLP-2
TB-500
GLP-2
Prostaglandin E2 stimulates GLP-1 and GLP-2 secretion and reduces glucose absorption in the perfused rat smal…
The Role of Vasoactive Intestinal Peptide in Glucagon-like Peptide-2-Mediated Intestinal Lipid Handling.
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowe…
+4 more
TB-500
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
About GLP-2
Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
GLP-2
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
GLP-2
TB-500
Where to source these peptides
GLP-2
11 listed
Browse directory →
Providers offeringTB-500
402 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). GLP-2 vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/glp-2/tb-500